Rapid progress on the next generation of therapeutic proteins and novel scaffolds, as well as emerging new drug classes and biologics, is currently being made in preclinical and clinical programs. Featuring four conferences, IBC's Next Generation Protein Therapeutics Summit brings together leading companies and academics from different disciplines to cross-fertilize ideas, share new data, and discuss strategies that will help you turn promising molecules into products.
| Monday, June 21 | Tuesday, June 22 | Wednesday, June 23 | |||
| Beyond Antibodies | |||||
| Protein Engineering & Design | |||||
| Immunogencity of Biologics | |||||
| Crossing the Barriers | |||||
IBC's 5th Annual Beyond Antibodies presents preclinical and clinical progress on multiple molecules, and highlights emerging companies like Bicycle Therapeutics, and Philogen so you can find novel approaches and lessons learned.
» Agenda | Download This Brochure
IBC's 4th Annual Protein Engineering & Design emphasizes strategies to improve drug-like properties of proteins to help you engineer more creative and robust molecules.
» Agenda | Download This Brochure
IBC's 1st Annual Immunogenicity of Biologics discusses multiple case studies from both antibody and alternative scaffold projects and presents preclinical and clinical strategies to mitigate immunogenicity that you can implement in your own lab.
» Agenda | Download This Brochure
IBC's 1st Annual Crossing the Barriers highlights novel approaches you can use to attack intracellular targets, find alternative protein delivery strategies and move your proteins and antibodies across the blood-brain-barrier and other membranes.
» Agenda | Download This Brochure
Don't Take Our Word For It, Hear What Your Peers Had to Say...
"I particularly liked the level of results/data presented and enjoyed the meeting as an excellent overview of the status of this field"
- Gunter Jagschies, Senior Director, Strategic Customer Relations, GE Healthcare (2009 Attendee)
"The most useful conference showing the latest developments in the field of next-generation protein therapeutics"
- Dragan Grabulovski, Chief Scientific Officer, Covagen (2009 Attendee)
"Speakers were amazingly candid and honest with their attempts, successes and failures"
- Eric Althoff, Head of Chemistry, Arzeda (2009 Attendee)
Copyright IBC Life Sciences, a part of Informa Life Sciences Group. | Phone: 800.390.4078 | Email: reg@ibcusa.com